Menu Search
Equities

Simcere Pharmaceutical Group Ltd

S2P:FRA

Simcere Pharmaceutical Group Ltd

Actions
  • Price (EUR)0.835
  • Today's Change0.09 / 12.08%
  • Shares traded1.26k
  • 1 Year change-0.60%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Simcere Pharmaceutical Group Ltd had net income fall -23.22% from 930.87m to 714.76m despite a 4.49% increase in revenues from 6.32bn to 6.61bn. An increase in the cost of goods sold as a percentage of sales from 20.99% to 24.57% was a component in the falling net income despite rising revenues.
Gross margin77.02%
Net profit margin-17.40%
Operating margin-17.47%
Return on assets-9.04%
Return on equity-13.82%
Return on investment-11.71%
More ▼

Cash flow in CNYView more

In 2023, Simcere Pharmaceutical Group Ltd increased its cash reserves by 21.04%, or 348.85m. Cash Flow from Investing totalled 1.09bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 151.05m in cash from operations while cash used for financing totalled 894.83m.
Cash flow per share-0.327
Price/Cash flow per share--
Book value per share2.92
Tangible book value per share2.46
More ▼

Balance sheet in CNYView more

Simcere Pharmaceutical Group Ltd has a Debt to Total Capital ratio of 14.61%, a higher figure than the previous year's 6.83%.
Current ratio2.10
Quick ratio1.88
Total debt/total equity0.1711
Total debt/total capital0.1461
More ▼

Growth rates in CNY

SmartText is unavailable
EPS growth(5 years)-2.62
EPS (TTM) vs
TTM 1 year ago		-135.26
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.